Eosinophilic Esophagitis Drug Markets, 2028 – Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan – ResearchAndMarkets.com

Eosinophilic Esophagitis Drug Markets, 2028 – Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan – ResearchAndMarkets.com




Eosinophilic Esophagitis Drug Markets, 2028 – Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Eosinophilic Esophagitis Drug Market Share, Size, Trends, Industry Analysis Report, By Product; By Diagnosis; By Treatment; By Regions; Segment Forecast, 2021-2028” report has been added to ResearchAndMarkets.com’s offering.

The global eosinophilic esophagitis drug market size is expected to reach US$ 189.7 million by 2028, according to the study.

The market for eosinophilic esophagitis drug is driven by the growing prevalence of type II inflammatory disorders including EoE, advances in the treatment procedures, and intense competition among players for the first FDA approved drug to have a first-mover advantage. Huge unmet in EoE is also favoring the growth of the eosinophilic esophagitis drug industry.

Diagnosis criteria of EoE are imperfect, as it is derived by expert opinions (with consensus between gastroenterologists, allergists, and pathologists), rather than being evidence-based. Currently, histologic criteria for EoE is not clear and it requires repeated tissue assessment to confirm disease onset, as there is no coherence between disease activity with patient symptoms.

Segment Highlights

  • The Dupilunab segment of the eosinophilic esophagitis drug industry accounted for the largest revenue share in 2020 as the majority of rare disease lies within neurology therapy area. Dupilunab market held over 25% of the global share in 2020.
  • Based on treatment, the dietary therapy segment for the eosinophilic esophagitis drug industry is projected to constitute almost half of the market in 2028. This can be attributed to current treatment based on a strict dietary regimen owing to the onset of EoE following food allergies.
  • North America region is dominating the global eosinophilic esophagitis market, holding almost one-third of the market share throughout forecast period. No FDA approved drugs and huge unmet medical needs are factors responsible for such growth.
  • The players including Bristol-Myers Squibb, Takeda (Shire), AstraZeneca, and Regeneron pharmaceuticals together hold a significant market share of the global market in 2020.

Market Dynamics

Drivers and Opportunities

  • Strong Drug Pipeline
  • Aging Population

Restraints and Challenges

  • Adverse Reactions

Porter’s Five Forces Analysis

PESTLE Analysis

List of Key Players

  • Regeneron Pharmaceuticals
  • Adare Pharmaceuticals, Inc.
  • Bristol-Myers Squibb
  • Takeda (Shire)
  • DBV Technologies
  • Falk Pharma GmbH
  • Allakos, Inc.
  • Arena Pharmaceuticals
  • Ception Therapeutics
  • Others

The analyst has segmented the eosinophilic esophagitis drug market report on the basis of product, diagnosis, treatment, and region:

Eosinophilic Esophagitis Drug, Product Outlook (Revenue-USD Million, 2016-2028)

  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab
  • QAX576
  • AKOO2
  • Losartan

Eosinophilic Esophagitis Drug, Diagnosis Outlook (Revenue-USD Million, 2016-2028)

  • Upper Endoscopy
  • Esophagus Biopsy
  • Blood Tests
  • Others

Eosinophilic Esophagitis Drug, Treatment Outlook (Revenue-USD Million, 2016-2028)

  • Dietary Therapy
  • Medication
  • Dilation
  • Others

Eosinophilic Esophagitis Drug, Regional Outlook (Revenue-USD Million, 2016-2028)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

For more information about this report visit https://www.researchandmarkets.com/r/3a4nvq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900